Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

The second-quarter results for Qiagen N.V. (NYSE:QGEN) were released last week, making it a good time to revisit its performance. It looks like the results were a bit of a negative overall. While revenues of US$534m were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 7.4% to hit US$0.44 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Following the latest results, Qiagen's 17 analysts are now forecasting revenues of US$2.08b in 2025. This would be an okay 2.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 7.0% to US$1.84. In the lead-up to this report, the analysts had been modelling revenues of US$2.07b and earnings per share (EPS) of US$1.89 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the small dip in their earnings per share numbers for next year.

View our latest analysis for Qiagen

It might be a surprise to learn that the consensus price target was broadly unchanged at US$52.04, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Qiagen analyst has a price target of US$60.00 per share, while the most pessimistic values it at US$45.00. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Qiagen's growth to accelerate, with the forecast 4.1% annualised growth to the end of 2025 ranking favourably alongside historical growth of 0.3% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.0% per year. It seems obvious that, while the future growth outlook is brighter than the recent past, Qiagen is expected to grow slower than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Qiagen. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Qiagen's revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$52.04, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Qiagen. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Qiagen analysts - going out to 2027, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Qiagen , and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.